BTG plc (BTG) Receives Consensus Recommendation of “Buy” from Brokerages
Shares of BTG plc (LON:BTG) have received a consensus recommendation of “Buy” from the nine ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is GBX 777.57 ($10.47).
Several research analysts have commented on the stock. J P Morgan Chase & Co reissued a “neutral” rating on shares of BTG in a report on Friday. Numis Securities restated a “buy” rating and set a GBX 900 ($12.11) price objective on shares of BTG in a research report on Friday. Deutsche Bank restated a “buy” rating and set a GBX 775 ($10.43) price objective on shares of BTG in a research report on Thursday, September 21st. Peel Hunt restated a “hold” rating and set a GBX 680 ($9.15) price objective on shares of BTG in a research report on Wednesday, September 20th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a GBX 800 ($10.77) target price on shares of BTG in a research report on Wednesday, August 30th.
Shares of BTG (BTG) opened at GBX 733.50 ($9.87) on Monday. BTG has a fifty-two week low of GBX 528.36 ($7.11) and a fifty-two week high of GBX 779 ($10.48).
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with MarketBeat.com's FREE daily email newsletter.